Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective-Reference-Cited by-同舟云学术

Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective

Published:2015-01-09 Issue:3 Volume:97 Page:247-262
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Jones HM¹,Chen Y²,Gibson C³,Heimbach T⁴,Parrott N⁵,Peters SA⁶,Snoeys J⁷,Upreti VV⁸,Zheng M⁹,Hall SD¹⁰

Affiliation:

1. Pfizer Worldwide Research & Development; Cambridge Massachusetts USA

2. Genentech; South San Francisco California USA

3. Merck Research Laboratories; West Point Pennsylvania USA

4. Novartis Institutes for Biomedical Research; East Hanover New Jersey USA

5. F. Hoffmann-La Roche Ltd; Basel Switzerland

6. Astrazeneca Research & Development; Mölndal Sweden

7. Janssen Research & Development; Beerse Belgium

8. Amgen; Seattle Washington USA

9. Bristol Myers Squibb Company; Pennington New Jersey USA

10. Eli Lily & Company; Indianapolis Indiana USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.37/fullpdf

Reference75 articles.

1. Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration;Teorell;Arch. Int. Pharmacodyn. Ther,1937

2. Drug interaction guideline for drug development and labeling recommendations (draft) 2014

Cited by 390 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration;European Journal of Pharmaceutical Sciences;2024-09

2. Application of Mechanistic Multiparameter Optimization and Large-Scale In Vitro to In Vivo Pharmacokinetics Correlations to Small-Molecule Therapeutic Projects;Molecular Pharmaceutics;2024-08-13

3. Physiologically based pharmacokinetic modeling in obesity: applications and challenges;Expert Opinion on Drug Metabolism & Toxicology;2024-08-12

4. Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19;Cancer Chemotherapy and Pharmacology;2024-08-07

5. Physiologically based pharmacokinetic modeling of CYP2C8 substrate rosiglitazone and its metabolite to predict metabolic drug-drug interaction;Drug Metabolism and Pharmacokinetics;2024-08